Cellectar Biosciences, Inc. Resources
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Technology
Overview
Posters & Publications
Product Pipeline
Overview
CLR 131
Clinical Trials
Overview
Relapsed or Refractory Multiple Myeloma Clinical Trial
Unknown status
Children With Relapsed or Refractory Malignant Cancer Clinical Trial
Recruiting
Relapsed or Refractory Select B-Cell Malignancies Clinical Trial
Recruiting
News & Media
Investors
Contact
Contact
Clinical Trials
Clinical Trials
Overview
Relapsed or Refractory Multiple Myeloma Clinical Trial
Children With Relapsed or Refractory Malignant Cancer Clinical Trial
Relapsed or Refractory Select B-Cell Malignancies Clinical Trial
Contact us for more information on the CLR 131 Clinical Trials
Name
Email
I am a:
Patient
Friend, Family, Caregiver
Physician/Healthcare Provider
Clinical Trial
Select Your Trial
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1)
Message